Pharmaceuticals Company Announces Study Results For Alcohol Disorder Treatment

In the ongoing battle against Alcohol Use Disorder (AUD), a ray of hope shines from the laboratories and clinical trial sites of Adial Pharmaceuticals, Inc. The company recently announced results from its latest study on AD04, a treatment option for AUD, which not only underscores the safety of the drug but also highlights the high level of patient compliance observed during the trial. This development could mark a significant step forward in the treatment of AUD, offering new hope to millions worldwide. Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, has long been dedicated to developing therapies for addiction and related disorders. Their lead investigational new drug, AD04, is at the forefront of this mission. The recent peer-reviewed publication in the European Journal of Internal Medicine provides detailed insights into the promising clinical results, robust safety profile, and high compliance among patients administered AD04. $Adial Pharmaceuticals(ADIL.US)$